Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 3, 2013, Pages 266-271

  Deliberato, Rodrigo Octavio ^a   Marra, Alexandre R ^a   Sanches, Paula Rodrigues ^a   Dalla Valle Martino, Marines ^a   Dos Santos Ferreira, Carlos Eduardo ^a   Pasternak, Jacyr ^a   Paes, Angela Tavares ^a   Pinto, Lilian Moreira ^a   Dos Santos, Oscar Fernando Pavão ^a   Edmond, Michael B ^b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic therapy; Antimicrobial therapy; Cost; Procalcitonin; Sepsis; Septic shock; Severe sepsis

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HUMAN; INFECTION RISK; INTENSIVE CARE; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CALCITONIN; COST SAVINGS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 84879187600     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.03.027     Document Type: Article

References (28)

1. Assiscot M., Gendrel D., Carsin H., Raymond J., Guilbaud J., Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341:515-518.
2. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
3. Bouadma L., Luyt C.E., Tubach F., et al. Use of procalcitonin to reduce patient's exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomized controlled trial. Lancet 2010, 375(9713):463-474.
4. Byl B., Clevenbergh P., Jacobs F., Struelens M.J., Zech F., Kentos A., et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999, 29:60-66.
5. Charlson M., Szatrowski T.P., Peterson J., et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47:1245-1251.
6. Chastre J., Wolff M., Fagon J.Y., Chevret S., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598.
7. Christ-Crain M., Jaccard-Stolz D., Bingisser R., et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomized, single-blinded intervention trial. Lancet 2004, 363:600-607.
8. Christ-Crain M., Stolz D., Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 168:2000-2007.
9. Clinical and Laboratory Standards Institute (CLSI) Principles and Procedures for Blood Culture; Approved Guideline, M47-A 2007, CLSI, Wayne, PA.
10. Fagon J.Y., Chastre J., Novara A., et al. Characterization of intensive care units patients using model based on the presence or absence of organ dysfunction and/or infection: the ODIN model. Intensive Care Med 1993, 19:137-144.
11. Hochreiter M., Kohler T., Schweiger A.M., et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009, 13:R83.
12. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E., et al. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
13. Le Gall J.R., et al. A new simplified acute physiology score (SAPS II) based on European/North American multicenter study. JAMA 1993, 270:2957-2963.
14. Marra A.R., de Almeida S.M., Correa L., et al. The effect of limiting antimicrobial therapy duration on antimicrobial resistance in the critical care setting. Am J Infect Control 2009, 37:204-209.
15. Mermel L.A., Allon M., Bouza E., et al. Clinical practice guidelines for the diagnoses and management of intravascular catheter related-bloodstream infection: 2009 update by the Infectious Disease Society of America. Clin Infect Dis 2009, 49:1-45.
16. Micek S.T., Ward S., Fraser V.J., Kollef M.H., et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004, 125:1791-1799.
17. Moussaoui R., de Borgie C.A., van den Broek P., et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomized, double blind study. BMJ 2006, 332:1355.
18. Muller B., Harbarth S., Stolz D., et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007, 7:10.
19. Nobre V., Harbarth S., Graf J.D., Rohner P., Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients. Am J Respir Crit Care Med 2008, 177:498-505.
20. Schuetz P., Christ-Crain M., Thomann R., et al. Effect of procalcitonin-based guidelines vs standard guidelines on atibiotica use in lower respiratory tract infection: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066.
21. Schuetz P., Albrich W., Christ-Crain M., Chastre J., Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010, 8:575-587.
22. Silvestre J., Povoa P., Coelho L., et al. Is C-reactive protein a good prognostic marker in septic patients?. Intensive Care Med 2009, 35:909-913.
23. Simon L., Gauvin F., Amre D.K., Saint-Louis P., Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004, 39:206-217.
24. Singh N., Rogers P., Atwood C.W., Wagener M.M., Yu V.L. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162:505-511.
25. Van der Meer V., Neven A.K., Van den Broek P.J., Assendelft W.J. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ 2005, 331:26.
26. Venkatesh B., Kennedy P., Kruger P.S., Looke D. Changes in serum procalcitonin and c-reactive protein following antimicrobial therapy as a guide to antibiotic duration in critically ill: a prospective evaluation. Anaesth Intensive Care 2009, 37:20-26.
27. Vicent J.L., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996, 22:707-710.
28. Yu V., Singh N. Excessive antimicrobial usage cause measurable harm to patients with suspected ventilator-associated pneumonia. Intensive Care Med 2004, 30:735-738.